Can We Repurpose Existing Drugs to Fight Aging? New Research Maps a Network-Medicine Path

Annual price tags for cutting-edge longevity therapies can reach six figures, with little insurance coverage to soften the cost. Yet a Nature Aging study published in June 2026 used a network medicine framework to identify 370 FDA-approved or experimental drugs that could potentially be repurposed to target aging processes. The prospect that effective anti-aging interventions might already exist on pharmacy shelves raises the question: why aren't public health systems racing to deploy them, and what would it take to shift longevity science from a luxury good to a civic resource?

Bnaya Gross and Albert-László Barabási at Northeastern University's Network Science Institute, working with Vadim N. Gladyshev and Joseph Loscalzo at Brigham and Women's Hospital and Harvard Medical School, mapped 2,358 longevity-associated genes onto the human protein interactome, assigning 1,250 genes to 11 hallmarks of aging. The researchers screened 6,442 clinically approved or experimental compounds from DrugBank using the SHARP (Systematic Hallmark-based Aging Repurposing Pipeline) framework.

The study uses a pAGE metric that compares drug-induced transcriptional changes against age-related shifts to distinguish pro-longevity from age-accelerating candidates. Between 14 and 21 drugs showed pro-longevity signals, depending on the confidence level used, while 14 to 23 drugs showed signals that they might accelerate aging.

"This study does not provide a cure for aging, nor does it prove that any specific drug will extend human life," Albert-László Barabási, Distinguished University Professor of Physics at Northeastern University's Network Science Institute, said. "It offers a roadmap … toward actionable interventions that can be tested in cells, animals and eventually humans."

A separate Nature Aging study published June 30, 2026, demonstrated that inhibiting telomeric DNA damage response signaling using telomeric antisense oligonucleotides (tASOs) rejuvenates hematopoietic and immune function in aged mice and human stem cells. Fabrizio d'Adda di Fagagna, Director of the research program Response to DNA damage and cellular senescence at IFOM ETS – The AIRC Institute of Molecular Oncology in Milan and Director of Research at the Institute of Molecular Genetics IGM-CNR in Pavia, led the study.

The treatment improved hematopoietic stem and progenitor cell fitness, restored myeloid-to-erythroid balance, reversed extramedullary hematopoiesis in both telomerase-deficient and physiologically aged wild-type mice, enhanced vaccine-induced antibody responses, and reduced inflammation and senescence markers. It also increased ex vivo colony-forming ability of CD34+ hematopoietic stem and progenitor cells from aged human donors. The benefits occur independently of telomere lengthening, suggesting that silencing the damage signal itself is sufficient for rejuvenation.

"Our results indicate that telomeric DNA damage signalling is not merely a consequence of telomere dysfunction," Fabrizio d'Adda di Fagagna said. "It is itself a causal driver of pathology."

Long-term tASO treatment showed no toxicity, no impaired global DNA damage response, and no tumor formation. Neither study establishes a clinical anti-aging therapy: no FDA-approved drug currently exists to slow aging in healthy adults, and the network medicine candidates have not yet proven clinical efficacy in humans.

Drug repurposing typically costs around USD 300 million—about 50 to 60 percent lower than de novo drug discovery—and compresses timelines to roughly 3 to 12 years versus 10 to 17 years for new molecular entities. Repurposed drugs can bypass new safety trials and move directly into Phase II or III efficacy testing, with approval rates around 30 percent. The combination of lower cost, faster timelines, and proven safety profiles makes longevity therapies derived from repurposing potentially compatible with Medicare budgets and public formularies.

Federal law generally bars Medicare coverage of drugs prescribed solely for anti-aging or longevity purposes as of 2026, and no drug currently has an approved human indication for aging or lifespan extension. Developers are therefore structuring clinical trials around specific age-related diseases and functional outcomes. In 2026, Medicare expanded access to GLP-1 medications when tied to specific medical indications like obesity and cardiometabolic risk, with popular drugs available for about $50 per month for qualifying beneficiaries—a precedent showing coverage can follow when indications are defined. Most commercial longevity practice still relies on approved products used off-label and non-approved compounds marketed as supplements or wellness interventions.

High costs and limited insurance coverage are making extended healthspan largely accessible to wealthy, well-educated populations, risking a widening of existing health and wealth gaps. Yet many early gerotherapeutic approaches are available at generic drug prices, making information and awareness key barriers to equitable access. Without deliberate policy and equity-focused frameworks, longevity innovations could entrench a tiered healthcare landscape where advanced life-extension is a luxury good rather than a broadly shared benefit.

Moving the network medicine study's candidate drugs from roadmap to clinic will require rigorous human trials structured around specific age-related diseases to satisfy FDA indication requirements and unlock Medicare coverage. Policy makers would need to create pathways that allow aging itself—or hallmark-specific functional endpoints—to serve as approvable indications, enabling repurposed drugs to enter formularies without waiting for disease-by-disease trials. Advocates and informed citizens can apply pressure at multiple points: funding agencies that prioritize repurposing trials, Medicare coverage policies that treat aging hallmarks as reimbursable conditions, and public-health campaigns that disseminate findings from studies like the Nature Aging network medicine analysis.